TrialActa neurologica Belgica2024

Comparing infusion-related reactions of the first full dose (600 mg) biosimilar ocrelizumab administration with the standard divided protocol in multiple sclerosis patients: a randomized controlled trial study.

Naghmeh Abbasi Kasbi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.